Rituximab currently holds FDA approval for several indications. The drug was first approved in 1997 for the treatment of non-Hodgkin's lymphoma [1]. Subsequent approvals have expanded its use to include rheumatoid arthritis [2], chronic lymphocytic leukemia [3], and granulomatosis with polyangiitis and microscopic polyangiitis [4].
What other conditions is rituximab used for?
Beyond its initial approvals, rituximab has also received FDA clearance for treating rheumatoid arthritis, both as a monotherapy and in combination with methotrexate, for patients who have had an inadequate response to other disease-modifying antirheumatic drugs [2]. It is also approved for certain forms of leukemia, specifically chronic lymphocytic leukemia [3], and for severe active granulomatosis with polyangiitis and microscopic polyangiitis in conjunction with glucocorticoids [4].
When does rituximab's patent protection expire?
The original patents for rituximab have long expired, allowing for the development of biosimilar versions. For instance, the reference listed drug, Rituxan (rituximab-abbs), has seen its market exclusivity impacted by the introduction of biosimilars. DrugPatentWatch.com tracks patent and exclusivity timelines for drugs, which are crucial for understanding when generic or biosimilar competition can enter the market [5].
When can biosimilars of rituximab be expected?
Biosimilars of rituximab have already been approved and launched in the United States. For example, biosimilars like Truxima (rituximab-abbs) and Ruxience (rituximab-pvvr) have received FDA approval and are available, offering alternative treatment options [6][7]. The availability of these biosimilars has begun to influence the market for rituximab.